Cervical cancer

Obstetrics and Gynecology

Volumn 107, Issue 5, 2006, Pages 1152-1161

  Moore, David H ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; HYDROXYUREA; IFOSFAMIDE; MITOLACTOL; PACLITAXEL; TOPOTECAN;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COLPOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; EARLY CANCER; HUMAN; LEUKOPENIA; METASTASIS; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SURVIVAL TIME; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER;

BIOPSY; DIAGNOSTIC IMAGING; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 33646765788     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000215986.48590.79     Document Type: Review

References (78)

1. American Cancer Society, Inc. Surveillance Research. Cancer facts and figures, 2005. Available at: http://www.cancer.org/downloads/STT/ CAFF2005f4PWSecured.pdf. Retrieved February 23, 2006.
2. Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. Cancer J 2003;9:348-59.
3. Cannistra SA, Niloff JM. Cancer of the uterine cervix. N Engl J Med 1996;334:1030-8.
4. Agarwal SS, Sehgal A, Sardana S, Kumar A, Luthra UK. Role of male behavior in cervical carcinogenesis among women with one lifetime sexual partner. Cancer 1993;72:1666-9.
5. Castellsague X, Bosch FX, Munoz N, Meijer CJLM, Shah KV, de Sanjose S, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002;346:1105-12.
6. Lambert PF, Pan H, Pitot HC, Liem A, Jackson M, Griep AE. Epidermal cancer associated with expression of human papillomavirus type 16 E6 and E7 oncogenes in the skin of transgenic mice. Proc Natl Acad Sci U S A 1993;90:5583-7.
7. Slattery ML, Robison LM, Schuman KL, French TK, Abbott TM, Overall JC Jr, et al. Cigarette smoking and exposure to passive smoke are risk factors for cervical cancer. JAMA 1989;261:1593-8.
8. Sood AK. Cigarette smoking and cervical cancer: meta-analysis and critical review of recent studies. Am J Prev Med 1991;7:208-13.
9. Hellberg D, Nilsson S, Haley NJ, Hoffman D, Wynder E. Smoking and cervical intraepithelial neoplasia: nicotine and cotinine in serum and cervical mucus in smokers and non-smokers. Am J Obstet Gynecol 1988;158:910-3.
10. Barton SE, Maddox PH, Jenkins D, Edwards R, Cuzick J, Singer A. Effect of cigarette smoking on cervical epithelial immunity: a mechanism for neoplastic change? Lancet 1988;2:652-4.
11. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahe C, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005;353:2158-68.
12. Tjalma WA, Arbyn M, Paavonen J, van Waes TR, Bogers JJ. Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer. Int J Gynecol Cancer 2004;14:751-61.
13. Is pelvic radiation beneficial in the postoperative management of stage Ib squamous cell carcinoma of the cervix with pelvic node metastasis treated by radical hysterectomy and pelvic lymphadenectomy? A report from the Presidential Panel at the 1979 Annual Meeting of the Society of Gynecologic Oncologists. Gynecol Oncol 1980;10:105-10.
14. Creasman WT. New gynecologic cancer staging. Gynecol Oncol 1995;58:157-8.
15. Fu YS, Berek JS. Minimal cervical cancer: definition and histology. In: Grundmann E, Beck L, editors. Minimal neoplasia: diagnosis and therapy. Recent Results in Cancer Research. Berlin, Germany: Springer-Verlag, 1988. p. 47-56.
16. Heller PB, Maletano JH, Bundy BN, Barnhill DR, Okagaki T. Clinical-pathologic study of stage IIB, III, and IVA carcinoma of the cervix: extended diagnostic evaluation for paraaortic node metastasis. A Gynecologic Oncology Group Study. Gynecol Oncol 1990;38:425-30.
17. Hricak H, Powell CB, Yu KK, Washington E, Subak LL, Stern JL, et al. Invasive cervical carcinoma: role of MR imaging in pretreatment work-up-cost minimization and diagnostic efficacy analysis. Radiology 1996;198:403-9.
18. Russell AH, Walter JP, Anderson MW, Zukowski CL. Sagittal magnetic resonance imaging in the design of lateral radiation treatment portals for patients with locally advanced squamous cancer of the cervix. Int J Radiat Oncol Biol Phys 1992;23:449-55.
19. Subak LL, Hricak H, Powell CB, Azizi L, Stern JL. Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging. Obstet Gynecol 1995;86:43-50.
20. Narayan K, Hicks RJ, Jobling T, Bernshaw D, McKenzie AF. A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: potential impact on treatment. Int J Gynecol Cancer 2001;11:263-71.
21. Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 2001;19:3745-9.
22. Yen TC, Ng KK, Ma SY, Chou HH, Tsai CS, Hsueh S, et al. Value of dual-phase 2-fluoro-2-deoxy-D-glucose positron emission tomography in cervical cancer [published erratum appears in J Clin Oncol 2004;22:209]. J Clin Oncol 2003;21:3651-8.
23. 18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 2004;22:2167-71.
24. Weiser EB, Bundy BN, Hoskins WJ, Heller PB, Whittington RR, DiSaia PJ, et al. Extraperitoneal versus transperitoneal selective paraaortic lymphadenectomy in the pretreatment surgical staging of advanced cervical carcinoma (a Gynecologic Oncology Group study). Gynecol Oncol 1989;33:283-9.
25. Querleu D, LeBlanc E, Castelain B. Laparoscopic pelvic lymphadenectomy in the staging of early carcinoma of the cervix. Am J Obstet Gynecol 1991;164:579-81.
26. Benedetti-Panici P, Maneschi F, Cutillo G, Congiu M, Franchi M, Amoroso M, et al. Laparoscopic abdominal staging in locally advanced cervical cancer. Int J Gynecol Cancer 1999;9:194-7.
27. Goff BA, Muntz HG, Paley PJ, Tamimi HK, Koh WJ, Greer BE. Impact of surgical staging in women with locally advanced cervical cancer. Gynecol Oncol 1999;74:436-42.
28. Moore DH, Stehman FB. What is the appropriate management of early stage cervical cancer (International Federation of Gynecology and Obstetrics Stages I and ILA), surgical assessment of lymph nodes, and role of therapeutic resection of lymph nodes involved with cancer? J Natl Cancer Inst Monogr 1996;21:43-6.
29. Petereit DG, Hartenbach EM, Thomas GM. Para-aortic lymph node evaluation in cervical cancer: the impact of staging upon treatment decisions and outcome. Int J Gynecol Cancer 1998;8:353-64.
30. Lai CH, Huang KG, Hong JH, Lee CL, Chou HH, Chang TC, et al. Randomized trial of surgical (extraperitoneal or laparoscopic) versus clinical staging in locally advanced cervical cancer. Gynecol Oncol 2003;89:160-7.
31. Van Nagell J, Greenwell N, Powell D, Donaldson ES, Hanson MB, Gay EC, et al. Microinvasive carcinoma of the cervix. Am J Obstet Gynecol 1983;145:981-91.
32. Kolstad P. Follow-up study of 232 patients with stage Ia1 and 411 patients with stage Ia2 squamous cell carcinoma of the cervix (microinvasive carcinoma). Gynecol Oncol 1989;33:265-72.
33. Takeshima N, Yanoh K, Tabata T, Nagai K, Hirai Y, Hasumi K. Assessment of the revised International Federation of Gynecology and Obstetrics staging for early invasive squamous cervical cancer. Gynecol Oncol 1999;74:165-9.
34. Ostor AG, Rome RM. Micro-invasive squamous cell carcinoma of the cervix: a clinico-pathologic study of 200 cases with long-term follow-up. Int J Gynecol Cancer 1994;4:257-64.
35. Andersen E, Husth M, Joerjenson A, Nielsen K. Laser conization for microinvasive carcinoma of the cervix: short-term results. Int J Gynecol Cancer 1993;3:183-5.
36. Tseng CJ, Horng SG, Soong YK, Hsueh S, Hsieh CH, Lin HW. Conservative conization for microinvasive carcinoma of the cervix. Am J Obstet Gynecol 1997;176:1009-10.
37. Gadducci A, Sartori E, Maggino T, Landoni F, Zola P, Cosio S, et al. The clinical outcome of patients with stage Ia1 and Ia2 squamous cell carcinoma of the uterine cervix: a Cooperation Task Force (CTF) study. Eur J Gynaecol Oncol 2003;24:513-6.
38. Hopkins MP, Morley GW. Microinvasive squamous cell carcinoma of the cervix. J Reprod Med 1994;39:671-3.
39. Creasman WT, Zaino RJ, Major FJ, DiSaia PJ, Hatch KD, Homesley HD. Early invasive carcinoma of the cervix (3 to 5 mm invasion): risk factors and prognosis. Am J Obstet Gynecol 1998;178:62-5.
40. Schorge JO, Lee KR, Flynn CE, Goodman A, Sheets EE. Stage IA1 cervical adenocarcinoma: definition and treatment. Obstet Gynecol 1999;93:219-22.
41. Balega J, Michael H, Hurteau J, Moore DH, Santiesteban J, Sutton GP, Look KY. The risk of nodal metastasis in early adenocarcinoma of the uterine cervix. Int J Gynecol Cancer 2004;14:104-9.
42. Webb JC, Key CR, Quails CR, Smith HO. Population-based study of microinvasive adenocarcinoma of the uterine cervix. Obstet Gynecol 2001;97:701-6.
43. McHale MT, Le TD, Burger RA, Gu M, Rutgers JL, Monk BJ. Fertility sparing treatment for in situ and early invasive adenocarcinoma of the cervix. Obstet Gynecol 2001;98:726-31.
44. Morley GW, Seski JC. Radical pelvic surgery versus radiation therapy for stage I carcinoma of the cervix (exclusive of microinvasion). Am J Obstet Gynecol 1976;126:785-98.
45. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997;350:535-40.
46. Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, et al. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 2005;23:7428-36.
47. Feeney DD, Moore DH, Look KY, Stehman FB, Sutton GP. The fate of the ovaries after radical hysterectomy and ovarian transposition. Gynecol Oncol 1995;56:3-7.
48. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy. A Gynecologic Oncology Group study. Gynecol Oncol 1999;73:177-83.
49. Nezhat CR, Burrell MO, Nezhat FR, Benigno BB, Welander CE. Laparoscopic radical hysterectomy with paraaortic and pelvic lymph node dissection. Am J Obstet Gynecol 1992;166:864-5.
50. Schneider A, Possover M, Kamprath S, Endisch U, Krause N, Noschel H. Laparoscopy-assisted radical vaginal hysterectomy modified according to Schauta-Stoeckel. Obstet Gynecol 1996;88:1057-60.
51. Roy M, Plante M. Pregnancies after radical vaginal trachelectomy for early-stage cervical cancer. Am J Obstet Gynecol 1998;179:1491-6.
52. Covens A, Shaw P, Murphy J, DePetrillo D, Lickrish G, Laframboise S, et al. Is radical trachelectomy a safe alternative to radical hysterectomy for patients with stage IA-B carcinoma of the cervix? Cancer 1999;86:2273-9.
53. Bernardini M, Barrett J, Seaward G, Covens A. Pregnancy outcomes in patients with radical trachelectomy. Am J Obstet Gynecol 2003;189:1378-82.
54. Rocconi RP, Estes JM, Leath CA, Kilgore LC, Huh WK, Straughn JM. Management strategies for stage IB2 cervical cancer: a cost-effectiveness analysis. Gynecol Oncol 2005;97:387-94.
55. Rutledge TL, Kamelle SA, Tillmanns TD, Gould NS, Wright JD, Cohn DE, et al. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? Gynecol Oncol 2004;95:70-6.
56. National Institutes of Health Consensus Development Conference statement on cervical cancer. April 1-3, 1996. Gynecol Oncol 1997;66:351-61.
57. Durrance FY, Fletcher GH, Rutledge FN. Analysis of central recurrent disease in stages I and II squamous cell carcinomas of the cervix on intact uterus. Am J Roentgenol Radium Ther Nucl Med 1969;106:831-8.
58. Gallion HH, van Nagell JR Jr, Donaldson ES, Hanson MB, Powell DE, Maruyama Y, et al. Combined radiation therapy and extrafascial hysterectomy in the treatment of stage IB barrel-shaped cervical cancer. Cancer 1985;56:262-5.
59. Eifel PJ, Morris M, Wharton JT, Oswald MJ. The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1994;29:9-16.
60. Keys HM, Bundy BN, Stehman FB, Okagaki T, Gallup DG, Burnett AF, et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol 2003;89:343-53.
61. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma [published erratum appears in N Engl J Med 1999;341:708]. N Engl J Med 1999;340:1154-61.
62. Sardi JE, Sananes CE, Giaroli AA, Bermudez A, Ferreira MH, Soderini AH, et al. Neoadjuvant chemotherapy in cervical carcinoma stage IIB: a randomized controlled trial. Int J Gynecol Cancer 1998;8:441-50.
63. Chang TC, Lai CH, Hong JH, Hsueh S, Huang KG, Chou HH, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. J Clin Oncol 2000;18:1740-7.
64. Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Giannarelli D, et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol 2002;20:179-88.
65. Tierney JF, Stewart LA, Parmar MK. Can the published data tell us about the effectiveness of neoadjuvant chemotherapy for locally advanced cancer of the uterine cervix? Eur J Cancer 1999;35:406-9.
66. Neoadjuvant chemotherapy for locally-advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Eur J Cancer 2003;39:2470-86.
67. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339-48.
68. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-43.
69. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally-advanced cervical cancer [published erratum appears in N Engl J Med 1999;341:708]. N Engl J Med 1999;340:1144-53.
70. Peters, WA 3rd, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JF, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-13.
71. National Cancer Institute. NCI issues clinical announcement on cervical cancer: chemotherapy plus radiation improves survival. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health. February 1999. Available at: http://www.cancer.gov/newscenter/cervicalcancer. Retrieved February 23, 2006.
72. Kuzuya K. Chemoradiotherapy for uterine cancer: current status and perspectives. Int J Clin Oncol 2004;9:458-70.
73. Cardenes HR, Moore DH, Long HJ, Randall ME. Treatment of recurrent vaginal, vulvar and cervical cancer. In: Gershenson DM, McGuire WP, Gore M, Quinn MA, Thomas GM, editors. Gynecologic cancer: controversies in management. Philadelphia (PA): Elsevier Science; 2004. p. 119-32.
74. Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J. cis-Platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group. Cancer 1981;48:899-903.
75. Omura GA, Blessing JA, Vaccarello L, Berman ML, Clarke-Pearson DL, Mutch DG, et al. A randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1997;15:165-71.
76. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group trial. J Clin Oncol 2004;22:3113-9.
77. Long HJ, Bundy BN, Grendys EC, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 2005;23:4626-33.
78. Omura GA. Current status of chemotherapy for cancer of the cervix. Oncology 1992;6:27-32.